Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Leigh Turner, Paul S Knoepfler

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

Original languageEnglish (US)
JournalCell Stem Cell
DOIs
StateAccepted/In press - 2016

Fingerprint

Marketing
Internet
Industry
Stem Cells
Direct-to-Consumer Advertising

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine
  • Genetics

Cite this

Selling Stem Cells in the USA : Assessing the Direct-to-Consumer Industry. / Turner, Leigh; Knoepfler, Paul S.

In: Cell Stem Cell, 2016.

Research output: Contribution to journalArticle

@article{ca2fa30d513041cc9463f46a00e6b177,
title = "Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry",
abstract = "Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.",
author = "Leigh Turner and Knoepfler, {Paul S}",
year = "2016",
doi = "10.1016/j.stem.2016.06.007",
language = "English (US)",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",

}

TY - JOUR

T1 - Selling Stem Cells in the USA

T2 - Assessing the Direct-to-Consumer Industry

AU - Turner, Leigh

AU - Knoepfler, Paul S

PY - 2016

Y1 - 2016

N2 - Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

AB - Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

UR - http://www.scopus.com/inward/record.url?scp=84978493321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978493321&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2016.06.007

DO - 10.1016/j.stem.2016.06.007

M3 - Article

C2 - 27374789

AN - SCOPUS:84978493321

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

ER -